Results 231 to 240 of about 259,973 (292)

Tumor‐Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities

Advanced Science, EarlyView.
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley   +1 more source

PD‐1/PD‐L1

The Japanese Journal of SURGICAL METABOLISM and NUTRITION, 2019
openaire   +2 more sources

PD-L1 and BCG response prediction [PDF]

Nature Reviews Urology, 2019
openaire   +2 more sources

From Cell‐Free Transcriptomes to Single‐Cell Landscapes: Biomarker Discovery and Originating Cell Alteration Analysis via Graph Matrix Factorization

Advanced Science, EarlyView.
CellFreeGMF traces plasma cfRNA to likely originating cell types by integrating single‐cell atlases with graph‐regularized matrix factorization. The method decomposes cfRNA profiles into sample–cell contributions to reconstruct pseudo single‐cell expression.
Wenxiang Zhang, Wenjing Zhang, Hang Wei, Shiyan Liu, Junliang Shang, Weijie Gong, Hanwen Cheng, Xiujuan Lei, Yuhui Kou, Baoguo Jiang   +9 more
wiley   +1 more source

Mammographic radiomics and breast density for predicting PD-L1 expression in breast cancer. [PDF]

Cancer Imaging
Zhao YS, Li H, Zhao CC, Wang YH, Wang P, Xie ZY, Ji Y, Lu H.   +7 more
europepmc   +1 more source

Pyroptosis‐Inducing Engineered Microparticles for Cancer Immunotherapy

Advanced Science, EarlyView.
Engineered microparticles co‐delivering geldanamycin and dual nanobodies induce targeted pyroptosis and block PD‐L1 and CD47 pathways, reprogramming the tumor microenvironment and achieving potent antitumor immunity in lung cancer models with minimal toxicity.
Tianli Hao, Zihan Deng, Yufei Liu, Li Liu, Deqiang Deng, Muyang Yang, Yuanyuan Geng, Yao Sun, Beilei Yue, Jonathan F. Lovell, Yushuai Liu, Lisen Lu, Honglin Jin   +12 more
wiley   +1 more source

Ubenimex synergizes with the PD-L1 blockade in gastric cancer by competitively binding LAP3 with UBE3A. [PDF]

Cell Death Dis
Zhao C, Li J, Zheng J, Chi M, Shao Y, Che Y, Chen W, Dai J, Chen C, Li X, Zan L, Shi Y, Duan Y, Yang L, Yang T.   +14 more
europepmc   +1 more source

ANXA2‐mediated Phagocytosis Generates AR+ Macrophages to Confer Enzalutamide Resistance in Prostate Cancer

Advanced Science, EarlyView.
A novel resistance mechanism is mediated through phagocytosis of cancer cells by AR+ TAMs. This process, dependent on ANXA2, enables macrophages to acquire AR protein from engulfed tumor cells. The internalized AR translocates into the macrophage nucleus, where it binds directly to the IL‐6 promoter, augmenting IL‐6 transcription and secretion ...
Yong Luo, Tianlong Luo, Lingfeng Li, Qi Sun, Dongquan Li, Shanhe Huang, Zonglin Li, Weilong Lin, Yuan Ou, Tao Du, Shengmeng Peng, Kewei Xu, Bisheng Cheng, Hai Huang   +13 more
wiley   +1 more source

Teriflunomide modulates the PD-1/PD-L1 axis and enhances antitumor immunity in colorectal cancer. [PDF]

Oncogenesis
Han JH, Lee EJ, Park YH, Ha JH, Ahmed KR, Choi JG, Chung HS.   +6 more
europepmc   +1 more source